Literature DB >> 15107982

[Prophylaxis and therapy of malaria in the practice].

C F R Hatz1.   

Abstract

Malaria prophylaxis is often discussed among travelers. Different recommendations are confusing. This is partially due to the availability of drugs in different countries and to the fact that few evidence-based data exist. German and Swiss experts try to counteract the resulting uncertainties by providing almost identical recommendations for malaria prevention and management. Many factors influence the malaria risk. Travel style, duration and season of travel, the transmitting anopheline mosquitoes, the causative Plasmodia and resistance of the parasites against antimalarial drugs influence the recommendations. Malaria protection consists of various components. Exposure prophylaxis substantially reduces the risk of infection. Drugs for chemoprophylaxis and standby emergency medications are available in industrialized countries. If malaria infection is readily diagnosed, the infection can always be successfully treated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15107982     DOI: 10.1007/s00108-004-1198-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  10 in total

1.  Efficacy of daily antimalarial chemoprophylaxis in tropical Africa using either doxycycline or chloroquine-proguanil; a study conducted in 1996 in the French Army.

Authors:  D Baudon; G Martet; B Pascal; J Bernard; A Keundjian; R Laroche
Journal:  Trans R Soc Trop Med Hyg       Date:  1999 May-Jun       Impact factor: 2.184

2.  Open questions in the case management of sick children.

Authors:  M Weber
Journal:  Trans R Soc Trop Med Hyg       Date:  2000 Jan-Feb       Impact factor: 2.184

Review 3.  Mefloquine for malaria chemoprophylaxis 1992-1998: a review.

Authors:  P Schlagenhauf
Journal:  J Travel Med       Date:  1999-06       Impact factor: 8.490

4.  Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team.

Authors:  B Høgh; P D Clarke; D Camus; H D Nothdurft; D Overbosch; M Günther; I Joubert; K C Kain; D Shaw; N S Roskell; J D Chulay
Journal:  Lancet       Date:  2000-12-02       Impact factor: 79.321

5.  Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study.

Authors:  D Overbosch; H Schilthuis; U Bienzle; R H Behrens; K C Kain; P D Clarke; S Toovey; J Knobloch; H D Nothdurft; D Shaw; N S Roskell; J D Chulay
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

6.  Use of malaria prevention measures by North American and European travelers to East Africa.

Authors:  H O Lobel; M A Baker; F A Gras; G M Stennies; P Meerburg; E Hiemstra; M Parise; M Odero; P Waiyaki
Journal:  J Travel Med       Date:  2001 Jul-Aug       Impact factor: 8.490

7.  Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa.

Authors:  R Steffen; E Fuchs; J Schildknecht; U Naef; M Funk; P Schlagenhauf; P Phillips-Howard; C Nevill; D Stürchler
Journal:  Lancet       Date:  1993-05-22       Impact factor: 79.321

8.  Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study.

Authors:  Patricia Schlagenhauf; Alois Tschopp; Richard Johnson; Hans D Nothdurft; Bernhard Beck; Eli Schwartz; Markus Herold; Bjarne Krebs; Olivia Veit; Regina Allwinn; Robert Steffen
Journal:  BMJ       Date:  2003-11-08

9.  Quinine loading dose in cerebral malaria.

Authors:  N J White; S Looareesuwan; D A Warrell; M J Warrell; P Chanthavanich; D Bunnag; T Harinasuta
Journal:  Am J Trop Med Hyg       Date:  1983-01       Impact factor: 2.345

10.  Tolerability of doxycycline monohydrate salt vs. chloroquine-proguanil in malaria chemoprophylaxis.

Authors:  Frédéric Pagès; Jean-Paul Boutin; Jean-Baptiste Meynard; Annick Keundjian; Serge Ryfer; Luciano Giurato; Dominique Baudon
Journal:  Trop Med Int Health       Date:  2002-11       Impact factor: 2.622

  10 in total
  1 in total

1.  [Status febrilis and unconsciousness].

Authors:  M Sawatzki; C Hatz; A Buser; M Battegay
Journal:  Internist (Berl)       Date:  2005-02       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.